Table 5.

Multivariate model for dissatisfaction

	OR (95% CI)	p value
BTP treatment		0.0002
Other vs FPNS	1.98 (1.42–2.76)
FBST vs FPNS	1.51 (1.03–2.21)
FBT vs FPNS	1.31 (0.86–1.99)
INFS vs FPNS	0.41 (0.14–1.24)
IV-M vs FPNS	0.47 (0.22–1.00)
SC-M vs FPNS	0.99 (0.50–1.94)
OM vs FPNS	1.35 (0.93–1.95)
OTFC vs FPNS	1.65 (0.95–2.88)
Place of assessment		0.04
Day hospital vs outpatient clinic	0.71 (0.45–1.13)
Home care vs outpatient clinic	0.29 (0.10–0.85)
Hospice vs outpatient clinic	0.52 (0.15–1.72)
Inpatient vs outpatient clinic	0.72 (0.51–1.03)
Previous anticancer treatment vs no previous anticancer treatment	1.41 (1.06–1.87)	0.0166
Care setting		0.0011
Palliative care vs oncology	0.84 (0.29–2.44)
Radiotherapy vs oncology	1.58 (0.54–4.59)
Pain therapy vs oncology	0.53 (0.38–0.74)

95% CI 95% confidence interval, BTP breakthrough pain, FBST fentanyl buccal sublingual tablet, FBT fentanyl buccal tablet, FPNS fentanyl pectin nasal spray, INFS intranasal fentanyl spray, IV-M intravenous morphine, OM oral morphine, OR odds ratio, OTFC oral transmucosal fentanyl citrate, SC-M subcutaneous morphine